slide1
Download
Skip this Video
Download Presentation
Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375

Loading in 2 Seconds...

play fullscreen
1 / 4

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375 - PowerPoint PPT Presentation


  • 99 Views
  • Uploaded on

Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375 Elizabeth Maestri, RN, [email protected] , 301-402-5633 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected] , 301-648-7375' - lelia


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide4
Summary of NIH HCL-specific trials –Robert J. Kreitman, M.D., [email protected], 301-648-7375
  • Elizabeth Maestri, RN, [email protected], 301-402-5633
  • Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (multicenter)
    • Multiply relapsed (prior purine analogs or purine analog + rituximab)
    • Recombinant immunotoxin, non-chemotherapy
    • No prior recombinant immunotoxin allowed
  • BRAF & MEK Inhibitors Dabrafenib & Trametinib for Hairy Cell Leukemia (multicenter)
    • Multiply relapsed (prior purine analogs or purine analog + rituximab)
    • Oral agents, taken daily
    • Must have BRAF V600E+ HCL
  • Randomized Phase II Trial of Rituximab With Pentostatin or Bendamustine for Multiply Relapsed HCL
    • Multiply relapsed
    • Pentostatin or bendamustine chemotherapy and rituximab monoclonal antibody
    • HCL or HCLv, prior recombinant immunotoxin or splenectomy allowed.
  • LMB-2 to Treat Hairy Cell Leukemia (NIH)
    • Multiply relapsed
    • Prior recombinant immunotoxin allowed
    • Recombinant immunotoxin, non-chemotherapy
  • Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia (NIH)
    • Early HCL: Newly diagnosed or once relapsed
    • Cladribine chemotherapy and rituximab monoclonal antibody
  • Multicenter study of BTK inhibitor Ibrutinib for relapsed HCL
    • Relapsed HCL or HCLv
    • Oral agent, taken daily
ad